Moxalactam treatment of anaerobic infections in cancer patients.

AUTOR(ES)

Lagast, H

RESUMO

Of 30 patients with predominantly anaerobic localized infections superimposed on chronic tissue damage related to trauma, ischemia, or tumor, 22 (73%) responded satisfactorily to moxalactam therapy. Moxalactam-resistant anaerobic pathogens emerged in two patients and were responsible for treatment failure. In six patients, two of whom also acquired resistant anaerobic pathogens, isolation of moxalactam-resistant aerobic pathogens increased during therapy.

Documentos Relacionados

• Mezlocillin for treatment of infections in cancer patients.
• Miconazole therapy for treatment of fungal infections in cancer patients.
• Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients.
• Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
• Imipenem versus moxalactam in the treatment of serious infections.